Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary
kidney disease and one of the most common causes of end-stage kidney disease. Multiple …

Purpose An increasing body of evidence suggests that excreting a generous volume of
diluted urine is associated with short-and long-term beneficial health effects, especially for …

Approval of the vasopressin V2 receptor antagonist tolvaptan—based on the landmark
TEMPO 3: 4 trial—marked a transformation in the management of autosomal dominant …

These recommendations were systematically developed on behalf of the Network for Early
Onset Cystic Kidney Disease (NEOCYST) by an international group of experts in autosomal …

There are an estimated 14,000 randomized trials published in chronic kidney disease. The
most frequently reported outcomes are biochemical endpoints, rather than clinical and …

Autosomal dominant polycystic kidney disease (ADPKD), the most common monogenic
cause of ESKD, is characterized by relentless development of kidney cysts, hypertension …

Autosomal dominant polycystic kidney disease (ADPKD) affects an estimated 1 in 1,000
people and slowly progresses to end-stage renal disease (ESRD) in about half of these …

Background Arginine vasopressin promotes kidney cyst growth in autosomal dominant
polycystic kidney disease (ADPKD). Increased water intake reduces arginine vasopressin …

Autosomal dominant polycystic kidney disease (ADPKD) is a heterogeneous genetic
disorder included in ciliopathies, representing the fourth cause of end stage renal disease …

Abstract Tolvaptan [Jynarque®(USA); Jinarc®(EU, Canada); Samsca®(Japan)] is a highly
selective vasopressin V 2 receptor antagonist approved for the treatment of autosomal …